Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported preliminary results from a Phase I dose-ranging study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, in rheumatoid arthritis. The compound was well tolerated at all doses evaluated, with no serious adverse events.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter